BTMD Q1 2024: 6.6% Procedure Growth Anchored in Existing Clinics as Internal Production Ramps
BTMD’s first quarter marked steady 6.6% procedure growth, underpinned by mature clinic expansion and a sharpened focus on onboarding higher-quality providers. The company’s internal production shift is progressing, though state licensing and inventory cycles will stagger the transition into year-end. Strategic investments in integration, new product innovation, and rapid provider training set the stage for a more vertically aligned and diversified business model in 2025.
Summary
- Clinic Maturity Drives Growth: Existing clinic expansion and up-tiering remain the main engine of procedure volume increases.
- Vertical Integration Progresses: Internalizing pellet production is on track, but licensing and inventory bleed-down will pace the shift.
- Therapeutic Wellness Pipeline Expands: New product innovation and provider education signal a broader platform for future growth.
Business Overview
BTMD operates in the therapeutic wellness sector, focusing on hormone optimization therapies delivered through a growing network of clinics. The company generates revenue primarily from procedure fees, product sales, and transaction fees on new wellness products. Major business segments include core hormone pellet therapies, new product categories such as GLP-1s, and ancillary offerings like nutraceuticals. BTMD is also pursuing vertical integration by bringing hormone pellet production in-house via its Asteria facility, aiming to enhance control over quality, margin, and supply chain.
Performance Analysis
Procedure growth of 6.6% year-over-year was driven primarily by existing clinics, with top-tier locations expanding their patient base and procedure volume. The company’s strategy of elevating second-tier clinics into higher-performing segments is showing traction, while new clinics—supported by the quick start onboarding program—are contributing a foundational layer for future growth but remain a smaller portion of current gains.
BTMD’s approach to new provider onboarding showed notable improvement, with management highlighting the highest quality of new customers since 2018. While the new product pipeline is advancing, its near-term financial impact is limited to transaction fees, as full manufacturing integration awaits regulatory milestones. The internalization of pellet production at Asteria is proceeding, though state licensing and inventory cycles are expected to stagger the transition through the remainder of 2024.
- Core Expansion: The majority of growth is from established clinics, with up-tiering efforts supporting volume.
- New Provider Quality: Focused targeting and onboarding are improving the caliber and engagement of new clinics.
- Integration Timing: Conversion to internal production will be gradual, dictated by state licensing and inventory drawdown.
Overall, the company’s steady core performance, improving onboarding, and early progress on vertical integration provide a solid foundation, but the full benefit of new product innovation and operational leverage will take time to materialize.
Executive Commentary
"Our geographic expansion is going very well. So we've seen real pockets of good uptake on the new providers that we're bringing to training and their ability to really go into those new markets and start a practice... So the expansion geographically is going well and we expect it to go well through the rest of the year and you'll be able to see those results second half of 24 and into 25 as those new markets develop."
Bob, Company Executive, Asteria
"When we look at the transaction fee and how it isn't going to be material to our year, when you think longer term, it would be great at some point to do what we're doing with this theory to be fully integrated. But at this point, we don't really have line of sight into executing that plan as of yet."
Terry, Company Executive, Asteria
Strategic Positioning
1. Clinic Network Optimization
BTMD’s growth strategy is anchored in maximizing performance from existing clinics, with a dual focus on expanding top-tier locations and upskilling second-tier sites. The company leverages its experienced sales force and targeted training programs to drive procedure volume and clinic maturation.
2. Accelerated Provider Onboarding
The quick start program, BTMD’s rapid onboarding initiative, is yielding a higher quality pipeline of new providers. Management reports that this is contributing to one of the strongest new provider cohorts since 2018, setting the stage for sustained growth in future periods as these clinics ramp up activity.
3. Vertical Integration and Production Control
The transition to internal pellet production at the Asteria facility is a key operational pivot, aimed at improving margin structure, quality assurance, and supply chain resilience. While the majority of production is expected to be internalized by year-end, execution is paced by state licensing and inventory cycles, particularly in states with unique regulatory timelines.
4. Diversification Through Therapeutic Wellness
BTMD is investing in new product development within the therapeutic wellness and healthy aging categories, including GLP-1s and nutraceuticals. Although near-term contributions are limited to transaction fees, the company is positioning itself as a comprehensive “one-stop shop” for providers, with education and integration of new therapies as a differentiator.
5. Data-Driven Sales and Customer Penetration
The sales force is increasingly data-driven, using internal analytics to identify opportunities for deeper penetration of existing clinics, cross-sell new products, and accelerate the transition of new providers into higher performance tiers.
Key Considerations
This quarter’s results reinforce BTMD’s focus on operational discipline, vertical integration, and strategic platform expansion—while highlighting the measured pace of transformation due to regulatory and market realities.
Key Considerations:
- Existing Clinic Growth Remains Central: The bulk of procedure growth is rooted in mature clinics, with up-tiering and targeted support driving incremental gains.
- Provider Onboarding Quality Improves: The quick start program is delivering a stronger, more engaged new clinic cohort, which should support future growth rates.
- Internal Production Faces Regulatory Friction: State licensing and inventory bleed-down will stagger the timing of full internalization, potentially delaying margin benefits.
- Product Innovation Pipeline Is Long-Term: New therapeutic wellness products are advancing, but meaningful revenue impact is a 2025-and-beyond story.
- Sales Force Effectiveness Is a Key Lever: Continued investment in sales training and analytics is critical to driving both existing and new clinic performance.
Risks
Execution risk remains elevated around the timing and completeness of the internal production transition, given dependency on state licensing and the pace of inventory drawdown at clinics. Regulatory hurdles, especially in states like California, may delay full integration. New product revenue is not expected to be material in the near term, and competitive pressures in hormone optimization and wellness could intensify as the market matures.
Forward Outlook
For Q2 2024, BTMD anticipates:
- Continued 6.6%+ procedure growth, with acceleration expected in the second half as new clinics ramp up and internal production scales.
- Gradual shift of pellet production to the Asteria facility, subject to regulatory approvals and inventory cycles.
For full-year 2024, management maintained its outlook for:
- Procedure revenue growth weighted to the back half, driven by mature clinic expansion and new provider onboarding.
Management highlighted several factors that will shape results:
- Regulatory progress on state licensing for internal production
- Uptake of new therapeutic wellness products and effectiveness of provider education
Takeaways
BTMD’s Q1 2024 results confirm steady core growth, operational focus, and early progress on strategic integration, but also underscore the measured pace of transformation and the lag in new product impact.
- Clinic-Driven Growth: Most procedure gains are from established clinics, with new provider quality and onboarding setting up future tailwinds.
- Integration and Innovation: Vertical integration is underway but will unfold gradually, and new product contribution is a longer-term lever.
- Future Watchpoint: Investors should monitor the cadence of state licensing, inventory transition, and the ramp of new clinics as key drivers for margin expansion and revenue acceleration in the second half and into 2025.
Conclusion
BTMD’s quarter delivered on expectations for core growth and operational discipline, while laying groundwork for a more integrated and diversified platform. The full benefits of these strategic moves will take time to materialize, making execution on licensing, onboarding, and innovation critical for the next phase of growth.
Industry Read-Through
BTMD’s experience highlights both the opportunity and friction in vertically integrating therapeutic wellness platforms. The measured pace of regulatory approvals and the importance of onboarding quality providers are themes likely to resonate across the broader wellness and healthcare services landscape. Competitors in hormone optimization and adjacent wellness therapies will face similar hurdles in scaling new product lines and integrating supply chains, while those with strong sales forces and data-driven provider support are best positioned to capture incremental growth. State-level regulatory complexity remains a key gating factor for expansion and margin realization industry-wide.